IRN research estimate that the medical expense element of personal injury and clinical negligence claims is valued at over £1 billion in 2020/21, of which CRU recoveries for NHS treatments represent around £200 million. Potentially, almost 30,000 private sector organisations could provide treatment services for personal injury claimants and over 1,000 NHS organisations could do likewise. The COVID-19 lockdowns caused a significant decline in personal injury case requiring treatment.
In terms of treatment revenue, RTA generate 38% of total revenue, followed by employer liability and public liability and finally clinical negligence cases, which represent 13% of treatment revenue (but only 2% of settled claims).
Without another serious wave of COVID, the treatment market is likely to grow over the coming years, although growth at the minor treatment end of the market will be harder to generate because of the new whiplash reforms.
DOWNLOAD report description